Semaglutide-Associated Acute Interstitial Nephritis: A Case Report
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are being investigated to slow the decline of kidney function in type 2 diabetics with chronic kidney disease (CKD). These agents have proven benefits on cardiac outcomes and all-cause mortality as well as in reducing the incidence of macroalbumin...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-12-01
|
| Series: | Kidney Medicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590059522001935 |
| _version_ | 1797987540533248000 |
|---|---|
| author | Megan Borkum Wynnie Lau Paula Blanco Myriam Farah |
| author_facet | Megan Borkum Wynnie Lau Paula Blanco Myriam Farah |
| author_sort | Megan Borkum |
| collection | DOAJ |
| description | Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are being investigated to slow the decline of kidney function in type 2 diabetics with chronic kidney disease (CKD). These agents have proven benefits on cardiac outcomes and all-cause mortality as well as in reducing the incidence of macroalbuminuria. Ours is a case of drug-associated acute interstitial nephritis requiring hemodialysis temporally related to a semaglutide dose increase. This case is unique as the index patient had no underlying CKD. Limited cases of acute kidney injury, superimposed on underlying CKD, in patients taking the GLP-1RA semaglutide have been reported. To our knowledge, there are no existing case reports in the literature of GLP-1RA-associated acute interstitial nephritis in a patient with baseline normal kidney function. Because our prescription of these agents is increasing and is anticipated to increase further with growing scientific evidence for their benefit, we sought to highlight this possible, important serious adverse effect of semaglutide. |
| first_indexed | 2024-04-11T07:49:55Z |
| format | Article |
| id | doaj.art-e412cad7fcc6404b9cbba4b361e08e6b |
| institution | Directory Open Access Journal |
| issn | 2590-0595 |
| language | English |
| last_indexed | 2024-04-11T07:49:55Z |
| publishDate | 2022-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Kidney Medicine |
| spelling | doaj.art-e412cad7fcc6404b9cbba4b361e08e6b2022-12-22T04:36:08ZengElsevierKidney Medicine2590-05952022-12-01412100561Semaglutide-Associated Acute Interstitial Nephritis: A Case ReportMegan Borkum0Wynnie Lau1Paula Blanco2Myriam Farah3Division of Nephrology, St Paul’s Hospital, Vancouver, Canada; Department of Medicine, University of British Columbia, Vancouver, Canada; Address for Correspondence: Megan Borkum, MD, Division of Nephrology, St Paul’s Hospital, Room 6010A, 1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada.Division of Nephrology, St Paul’s Hospital, Vancouver, CanadaDepartment of Medicine, University of British Columbia, Vancouver, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, CanadaDivision of Nephrology, St Paul’s Hospital, Vancouver, Canada; Department of Medicine, University of British Columbia, Vancouver, CanadaGlucagon-like peptide 1 receptor agonists (GLP-1RAs) are being investigated to slow the decline of kidney function in type 2 diabetics with chronic kidney disease (CKD). These agents have proven benefits on cardiac outcomes and all-cause mortality as well as in reducing the incidence of macroalbuminuria. Ours is a case of drug-associated acute interstitial nephritis requiring hemodialysis temporally related to a semaglutide dose increase. This case is unique as the index patient had no underlying CKD. Limited cases of acute kidney injury, superimposed on underlying CKD, in patients taking the GLP-1RA semaglutide have been reported. To our knowledge, there are no existing case reports in the literature of GLP-1RA-associated acute interstitial nephritis in a patient with baseline normal kidney function. Because our prescription of these agents is increasing and is anticipated to increase further with growing scientific evidence for their benefit, we sought to highlight this possible, important serious adverse effect of semaglutide.http://www.sciencedirect.com/science/article/pii/S2590059522001935Acute interstitial nephritisacute kidney injuryglucagon-like peptide 1 receptor agonistssemaglutide |
| spellingShingle | Megan Borkum Wynnie Lau Paula Blanco Myriam Farah Semaglutide-Associated Acute Interstitial Nephritis: A Case Report Kidney Medicine Acute interstitial nephritis acute kidney injury glucagon-like peptide 1 receptor agonists semaglutide |
| title | Semaglutide-Associated Acute Interstitial Nephritis: A Case Report |
| title_full | Semaglutide-Associated Acute Interstitial Nephritis: A Case Report |
| title_fullStr | Semaglutide-Associated Acute Interstitial Nephritis: A Case Report |
| title_full_unstemmed | Semaglutide-Associated Acute Interstitial Nephritis: A Case Report |
| title_short | Semaglutide-Associated Acute Interstitial Nephritis: A Case Report |
| title_sort | semaglutide associated acute interstitial nephritis a case report |
| topic | Acute interstitial nephritis acute kidney injury glucagon-like peptide 1 receptor agonists semaglutide |
| url | http://www.sciencedirect.com/science/article/pii/S2590059522001935 |
| work_keys_str_mv | AT meganborkum semaglutideassociatedacuteinterstitialnephritisacasereport AT wynnielau semaglutideassociatedacuteinterstitialnephritisacasereport AT paulablanco semaglutideassociatedacuteinterstitialnephritisacasereport AT myriamfarah semaglutideassociatedacuteinterstitialnephritisacasereport |